Peter Ellmark

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 12

Top Topics

Top Venues

Expert opinion on biological therapy

Cancer immunology, immunotherapy : CII

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark
Next-generation CD40 agonists for cancer immunotherapy. Expert opinion on biological therapy 24 (5) (2024)
Viktor Sincic, Ken F Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Gottfrid Sjödahl, Mats Wokander, Karin Hägerbrand, Peter Ellmark, Thoas Fioretos, Carl A K Borrebaeck, Fredrik Liedberg, Kristina Lundberg
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes. Cells 13 (11) (2024)
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark
Next generation CD40 agonists for cancer immunotherapy. Expert opinion on biological therapy (2024)
Viktor Sincic, Ken F Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Gottfrid Sjödahl, Mats Wokander, Karin Hägerbrand, Peter Ellmark, Thoas Fioretos, Carl A K Borrebaeck, Fredrik Liedberg, Kristina Lundberg
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes. Cells 13 (11) (2024)
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark
Next-generation CD40 agonists for cancer immunotherapy. Expert opinion on biological therapy 24 (5) (2024)
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark
Next-generation CD40 agonists for cancer immunotherapy. Expert opinion on biological therapy (2024)
Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt, Peter Ellmark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody. Cells 12 (19) (2023)
Karin Enell Smith, Sara Fritzell, Anneli Nilsson, Karin Barchan, Anna Rosén, Lena Schultz, Laura Varas, Anna Säll, Nadia Rose, Maria Håkansson, Laura von Schantz, Peter Ellmark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer immunology, immunotherapy : CII (2023)
Karin Hägerbrand, Laura Varas, Adnan Deronic, Barnabas Nyesiga, Anette Sundstedt, Lill Ljung, Christina Sakellariou, Doreen Werchau, Mia Thagesson, David Gomez-Jimenez, Lennart Greiff, Mona Celander, Kristine Smedenfors, Anna Rosén, Deniz Bölükbas, Fredrika Carlsson, Mattias Levin, Anna Säll, Laura von Schantz, Malin Lindstedt, Peter Ellmark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. Journal for immunotherapy of cancer 10 (11) (2022)
Michelle H Nelson, Sara Fritzell, Robert Miller, Doreen Werchau, Danielle Van Citters, Anneli Nilsson, Lynda Misher, Lill Ljung, Robert Bader, Adnan Deronic, Allison G Chunyk, Lena Schultz, Laura A Varas, Nadia Rose, Maria Håkansson, Jane Gross, Christina Furebring, Peter Pavlik, Anette Sundstedt, Niina Veitonmäki, Hilario J Ramos, Anna Säll, Anna Dahlman, David Bienvenue, Laura von Schantz, Catherine J McMahan, Maria Askmyr, Gabriela Hernandez-Hoyos, Peter Ellmark
The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies. Molecular cancer therapeutics (2022)
Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Karin Enell Smith, Peter Ellmark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer immunology, immunotherapy : CII 70 (12) (2021)
Peter Ellmark, Sara M Mangsbo, Christina Furebring, Per Norlén, Thomas H Tötterman
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer immunology, immunotherapy : CII 66 (1) (2016)